Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28680226 | 0.91 | TNF (0.56) | TNFMEN1MAPK1KMT2AL3MBTL1 | |
| SCHEMBL24813373 | 0.89 | TNF (0.49) | TNFMEN1MAPK1KMT2AL3MBTL1 | |
| SCHEMBL29144184 | 0.89 | TNF (0.49) | TNFMEN1MAPK1KMT2AL3MBTL1 | |
| SCHEMBL30049141 | 0.89 | TNF (0.49) | TNFMEN1MAPK1KMT2AL3MBTL1 | |
| SCHEMBL2168112 | 0.87 | ALDH1A1 (0.51) | TNFMEN1MAPK1KMT2AL3MBTL1 | |
| SCHEMBL10074262 | 0.85 | TNF (0.55) | TNFMEN1MAPK1KMT2AL3MBTL1 | |
| SCHEMBL3500695 | 0.82 | ALDH1A1 (0.56) | TNFMEN1MAPK1KMT2AL3MBTL1 | |
| SCHEMBL2282489 | 0.81 | MEN1 (0.54) | TNFMEN1MAPK1KMT2AALDH1A1 | |
| SCHEMBL2282582 | 0.81 | MEN1 (0.54) | TNFMEN1MAPK1KMT2AALDH1A1 | |
| SCHEMBL2168623 | 0.81 | MEN1 (0.54) | TNFMEN1MAPK1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150284329-A1 | Methods for synthesizing 3-(Substituted Dihydroisoindolinone-2-YI)-2, 6-Dioxopiperidine, and intermediates thereof | Nanjing Cavendish Bio-Engineering Technology Co., Ltd. (CN) | 2015-10-08 | — | — | US | disclosed |
| US-9085530-B2 | Methods for synthesizing 3-(substituted dihydroisoindolinone-2-yl)-2, 6-dioxopiperidine, and intermediates thereof | Nanjing Cavendish Bio-Engineering Technology Co., Ltd. (CN) | 2015-07-21 | — | — | US | disclosed |
| US-9085530-B2 | Methods for synthesizing 3-(substituted dihydroisoindolinone-2-yl)-2, 6-dioxopiperidine, and intermediates thereof | Nanjing Cavendish Bio-Engineering Technology Co., Ltd. (CN) | 2015-07-21 | — | — | US | disclosed |
| EP-2438053-B1 | METHODS FOR SYNTHESIZING 3-(SUBSTITUTED DIHYDROISOINDOLINONE-2-YL)-2,6-DIOXOPIPERIDINE, AND INTERMEDIATES THEREOF | NANJING CAVENDISH BIO ENGINEERING TECHNOLOGY CO LTD (CN) | 2013-09-11 | — | — | EP | disclosed |
| US-20120077982-A1 | Methods for Synthesizing 3-(Substituted Dihydroisoindolinone-2-YL)-2, 6-Dioxopiperidine, and Intermediates Thereof | Nanjing Cavendish Bio-Engineering Technology Co., Ltd. (CN) | 2012-03-29 | — | — | US | disclosed |
| US-20120077982-A1 | Methods for Synthesizing 3-(Substituted Dihydroisoindolinone-2-YL)-2, 6-Dioxopiperidine, and Intermediates Thereof | Nanjing Cavendish Bio-Engineering Technology Co., Ltd. (CN) | 2012-03-29 | — | — | US | disclosed |
| WO-2010139266-A1 | METHODS FOR SYNTHESIZING 3-(SUBSTITUTED DIHYDROISOINDOLINONE-2-YL)-2,6-DIOXOPIPERIDINE, AND INTERMEDIATES THEREOF | Nanjing Cavendish Bio-Engineering Technology Co., Ltd. (CN) | 2010-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150284329-A1 | Methods for synthesizing 3-(Substituted Dihydroisoindolinone-2-YI)-2, 6-Dioxopiperidine, and intermediates thereof | DHPS, QDPR, FDPS | TNF 1790/4885MEN1 3917/4885MAPK1 3302/4885 |
| US-20120077982-A1 | Methods for Synthesizing 3-(Substituted Dihydroisoindolinone-2-YL)-2, 6-Dioxopiperidine, and Intermediates Thereof | DHPS, QDPR, FDPS | TNF 2065/4885MEN1 3703/4885MAPK1 3195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.